Business
Personalis, Inc. Announces the Launch of the NeXT Dx™ Test, a Comprehensive Genomic Cancer Profiling Test Enabling Advanced Composite Biomarkers for Cancer Treatment
MENLO PARK, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of the NeXT Dx™
About this update from Personalis, Inc.
[{"type":"text","content":" MENLO PARK, Calif.--(BUSINESS WIRE)--\nPersonalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of the NeXT Dx™ Test to help oncologists identify potential therapies and clinical trial options for cancer patients. The Personalis NeXT Dx™ Test is one of the first cancer diagnostic platforms to profile approximately 20,000 genes in both the tumor exome and transcriptome, providing a comprehensive genomic testing solution that goes beyond many existing cancer diagnostic panels that focus on a few hundred genes. The Personalis NeXT Dx Test includes advanced analytics to provide a diagnostic report on genetic alterations in medically-important cancer genes, as well as emerging immunotherapy composite biomarkers of medical importance. Additionally, immunotherapy-related biomarkers such as microsatellite instability (MSI) status and tumor mutational burden (TMB) are included in the clinical report.\n\n\n“With new cancer immunotherapy and combination therapies, there is an increasing need for the development of more advanced composite biomarkers that can model the complex biology driving the response and resistance to cancer therapy. Our NeXT Dx Test provides oncologists with clinical reports on key diagnostic markers driving therapies today as well as provides information that can support the identification of new, advanced biomarkers. With the NeXT Dx Test, we look forward to expanding engagements with both leading clinical cancer centers as well as biopharmaceutical companies looking to push forward cutting-edge precision medicine in cancer,” said Dr. Richard Chen, MD, Chief Scientific Officer at Personalis.\n\n\nAbout NeXT Dx Test\n\n\nThe NeXT Dx Test, optimized for formalin-fixed, paraffin-embedded tumor samples, is a laboratory-developed test performed at Personalis’ CAP-accredited and CLIA’88-certified laboratory. The test utilizes ImmunoID NeXT™, a high-accuracy, clinical-grade, next-generation sequencing and analysis platform, to report base substitutions, insertions/deletions, gene fusions, and copy number alterations in cancer driver genes of clinical significance. Additionally, MSI status is reported based on five canonical loci (BAT25, BAT26, NR-21, NR-24, and NR-27), and TMB status is reported by leveraging the exome-wide analysis of non-synonymous somatic mutations. Based on ...